Northern Trust Corp Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Northern Trust Corp lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 5.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 385,157 shares of the specialty pharmaceutical company's stock after acquiring an additional 20,490 shares during the quarter. Northern Trust Corp owned approximately 1.19% of Collegium Pharmaceutical worth $11,035,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MetLife Investment Management LLC grew its stake in shares of Collegium Pharmaceutical by 8.5% during the 4th quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after acquiring an additional 1,558 shares during the period. Barclays PLC boosted its stake in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after purchasing an additional 45,291 shares during the period. Sanctuary Advisors LLC boosted its stake in Collegium Pharmaceutical by 5.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock worth $542,000 after purchasing an additional 952 shares during the period. Franklin Resources Inc. boosted its stake in Collegium Pharmaceutical by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock worth $1,164,000 after purchasing an additional 3,620 shares during the period. Finally, Amundi boosted its stake in Collegium Pharmaceutical by 188.3% in the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock worth $446,000 after purchasing an additional 10,168 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have commented on COLL shares. Piper Sandler restated a "neutral" rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC restated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded down $0.65 on Thursday, hitting $28.82. The company's stock had a trading volume of 224,620 shares, compared to its average volume of 428,024. The company has a 50-day simple moving average of $28.13 and a 200 day simple moving average of $29.77. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a market capitalization of $926.04 million, a PE ratio of 12.42 and a beta of 0.63. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. During the same period in the previous year, the business earned $1.45 EPS. The business's revenue was up 22.7% on a year-over-year basis. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the transaction, the executive vice president now directly owns 108,137 shares in the company, valued at approximately $3,081,904.50. This represents a 19.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 in the last 90 days. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.